Launched in 2016 with inaugural meetings in Manchester and Birmingham, UK, which I chaired. Though variations involving nations mean that a “one size fits all” approach is impossible, the localization from the program has demonstrated that common challenges exist, to which solutions based around the experiences of others, modifiedsubmit your manuscript www.dovepress.comAdvances in Medical Education and Practice 2017:DovepressDovepressThe INNOVATE educational initiativeor otherwise, could be PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21324630 applied. Two examples of these regional and country initiatives are provided beneath. Russia In Russia, vascular surgeons tend to take the lead in DVT management in consultation with hematologists and clinical pharmacology specialists, and there is certainly a stronger emphasis on interventional approaches for VTE therapy. As well as acute therapy, vascular surgeons also oversee the ambulatoryoutpatient management of individuals along with the patient’s common practitioner (GP). The nurse-led model of thrombosis care utilised in London and Sheffield would not yet be accepted in Russia. Nevertheless, several prominent Russian physicians attended one of several worldwide INNOVATE meetings in London, and subsequently I went to Russia to chair an INNOVATE kick-off MedChemExpress MK-7622 meeting in Saint Petersburg in December 2014. The attendees have been 14 “champions” for INNOVATE in Russia who wanted to setup regional INNOVATE meetings in seven centers of excellence across the nation. In the end, it is actually hoped that this network will result in the adoption of normal algorithms and protocols into national guidelines as well as other regulatory documents. Asia acific region The management of VTE in Australia differs significantly among geographical areas and hospitals, top to an inconsistent common of diagnosis, remedy, and management of sufferers across the country. You’ll find also distinct funding models in unique states and also a lack of guidance for GPs and others treating individuals in the neighborhood, at the same time because the challenge in rural communities of geographical isolation from core services. Owing to differences in the organization of solutions, Bayer Australia worked with an professional group in the Australian Society of Thrombosis and Haemostasis (ASTH) to setup an agenda for an initial pan-Australian INNOVATE meeting comprising a multidisciplinary faculty and participant group. Dr Rhona Maclean, co-chair on the Sheffield meeting, was invited to provide an overview from the Sheffield VTE pathway and of INNOVATE a lot more broadly. Challenges inside the Australian delivery of VTE services and specific case studies relating towards the NOACs had been discussed. The response towards the meeting was overwhelmingly constructive, and further meetings are planned. The ASTH intends to use INNOVATE to drive the improvement of common care pathways. A comparable model was made use of in other components in the AsiaPacific area, using a multi-country meeting taking location in Singapore, chaired by me and Dr David Kiely, who co-chairsmeetings in Sheffield. Each of these meetings highlighted a great diversity in practice but in the same time typical places from which learnings may be drawn. The following stage would be to bring INNOVATE towards the regional level in these nations.Implementing learnings from INNOVATE in neighborhood VTE protocolsThe practical added benefits of INNOVATE have already been demonstrated by the creation and strengthening of existing systems for VTE patient management, driven by participants who’ve attended meetings. Two examples are presented below.Central Alberta.